Analyst Price Target is $56.67
▲ +14.83% Upside Potential
This price target is based on 9 analysts offering 12 month price targets for Glaukos in the last 3 months. The average price target is $56.67, with a high forecast of $68.00 and a low forecast of $44.00. The average price target represents a 14.83% upside from the last price of $49.35.
Current Consensus is
The current consensus among 9 polled investment analysts is to buy stock in Glaukos. This rating has held steady since June 2022, when it changed from a Hold consensus rating.
Glaukos Corp. is an ophthalmic medical technology and pharmaceutical company, which focuses on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases. It engages in development and commercialization of therapies across several end markets within ophthalmology. The company was founded by Olav B. Bergheim, Morteza Gharib, and Richard Hill on July 14, 1998 and is headquartered in San Clemente, CA.